Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

Published:2018-11-08 Issue:1 Volume:49 Page:69-76
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Ito Keiichi¹,Masunaga Ayako¹,Tanaka Nobuyuki²³,Mizuno Ryuichi²^ORCID,Shirotake Suguru⁴,Yasumizu Yota⁴,Ito Yujiro⁵,Miyazaki Yasumasa²,Hagiwara Masayuki⁶,Kanao Kent²,Mikami Shuji⁷,Momma Tetsuo⁸,Masuda Takeshi³,Nakagawa Ken⁶,Oyama Masafumi⁴,Asano Tomohiko¹,Oya Mototsugu²

Affiliation:

1. Department of Urology, National Defense Medical College, Saitama, Japan

2. Department of Urology, Keio University School of Medicine, Tokyo, Japan

3. Department of Urology, Saitama City Hospital, Saitama, Japan

4. Department of Urology, Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan

5. Department of Urology, Saiseikai Central Hospital, Tokyo, Japan

6. Department of Urology, Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Chiba, Japan

7. Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan

8. Department of Urology, National Hospital Organization Saitama Hospital, Saitama, Japan

Funder

Ministry of Education, Culture, Sports, Science, and Technology of Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/49/1/69/27565478/hyy154.pdf

Reference23 articles.

1. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008);Wahlgren;Br J Cancer,2013

2. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma;Négrier;Eur J Cancer,2014

3. Early tumour shrinkage: a tool for the detection of early clinical activity in metastatic renal cell carcinoma;Grünwald;Eur Urol,2016

4. Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline;Claret;Cancer Chemother Pharmacol,2016

5. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy;Nakaigawa;BMC Cancer,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab;International Journal of Clinical Oncology;2024-07-24

2. The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-07

3. Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring;Cancers;2023-10-11

4. Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma;Urologic Oncology: Seminars and Original Investigations;2023-09

5. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors;World Journal of Urology;2021-03-01